ライフサイエンスコーパス: glycosaminoglycan

1 ialic acids and 2.4% equivalents of sulfated glycosaminoglycans).

2 ifically degrade heparan sulfate, a sulfated glycosaminoglycan.

3 nteraction is blocked by heparin, a sulfated glycosaminoglycan.

4 PF4 when it binds to CS, the major platelet glycosaminoglycan.

5 ranslational modifications apart from the CS glycosaminoglycan.

6 cable for labeling and detection of suitable glycosaminoglycans.

7 es high mannose-type N-glycans and decreases glycosaminoglycans.

8 e representatives of two major subclasses of glycosaminoglycans.

9 well to cells that are deficient in surface glycosaminoglycans.

10 s, reduced extracellular matrix proteins and glycosaminoglycans.

11 gradient is immobilized via interaction with glycosaminoglycans.

12 hat result from defects in the catabolism of glycosaminoglycans.

13 udge, focussing on sialic acids and sulfated glycosaminoglycans.

14 ediated by either elastin-binding protein or glycosaminoglycans.

15 antity and sulfation patterns of circulating glycosaminoglycans.

16 sosomal enzyme required for the breakdown of glycosaminoglycans.

17 fications observed previously on holothuroid glycosaminoglycans.

18 ncentrations of ApoB and ApoE, which bind to glycosaminoglycans.

19 to be enhanced by heparin and other sulfated glycosaminoglycans.

20 e extended to produce other isotope-enriched glycosaminoglycans.

21 Hyaluronic acid (HA) is a large glycosaminoglycan abundant in mammalian tissues that has

22 Heparan sulfate (HS) is a sulfated glycosaminoglycan abundant on the cell surface and in th

23 like structures, while staining demonstrated glycosaminoglycan accumulation.

24 s (VACV) envelope protein D8 is one of three glycosaminoglycan adhesion molecules and binds to the li

25 f AF-specific extracellular matrix (sulfated glycosaminoglycan and collagen type I), indicating a fav

26 content and orientation, water content, and glycosaminoglycan and/or proteoglycan content both in th

27 It binds glycosaminoglycans and certain phospholipids that can mo

28 ace glycocalyx with upregulation of sulfated glycosaminoglycans and charged glycoproteins.

29 ort that such ligands can be obscured by the glycosaminoglycans and glycoproteins that coat pathogeni

30 provide evidence that UpaB can interact with glycosaminoglycans and host fibronectin.

31 ere we show that gG attaches to cell surface glycosaminoglycans and induces lipid raft clustering, in

32 ssays that measured direct binding of Tau to glycosaminoglycans and inhibition of Tau uptake and seed

33 ptide-modified surfaces that can engage both glycosaminoglycans and integrins are effective.

34 Here, we measured vaspin binding of various glycosaminoglycans and low molecular weight heparins by

35 in many biopolymers including the polyanions glycosaminoglycans and nucleic acids.

36 ht to assess the alterations to structure of glycosaminoglycans and proteins that occur in PD brain r

37 composed of protein fibrils, hyper-sulphated glycosaminoglycans and serum amyloid P component (SAP).

38 Viral glycan receptors such as glycosaminoglycans and sialic acid-containing carbohydra

39 d infection of HCT-8 cells were inhibited by glycosaminoglycans and were reduced after heparan sulfat

40 ng, the cartilage was assayed for its water, glycosaminoglycan, and collagen content.

41 ated by treatment with trypsin or removal of glycosaminoglycans, and also suppressed by inhibition of

42 glycans, including N- and O-linked glycans, glycosaminoglycans, and carbohydrate antigens, an abilit

43 matched WT controls, including early loss of glycosaminoglycans, and decreased cartilage thickness an

44 Glycosaminoglycans are a group of negatively charged het

45 Because negatively charged glycosaminoglycans are abundantly present in this layer,

46 The sulfation patterns of these glycosaminoglycans are highly variable, which presents a

47 ich applies both in vitro and in vivo, where glycosaminoglycans are strongly associated with amyloid

48 at heparan sulfate and other closely related glycosaminoglycans are the molecules that are used by fi

49 a pointed out that sialic acids and sulfated glycosaminoglycans are worth investigating in the contex

50 roteolysis at a site predicted to generate a glycosaminoglycan-bereft N-terminal fragment, versikine

51 s could potentially be attributed to reduced glycosaminoglycan binding ability, as surface plasmon re

52 nents including collagens, proteoglycans and glycosaminoglycan binding molecules.

53 Structural analyses reveal glycosaminoglycan binding sites on Notum, which probably

54 ins: the glycoprotein, which plays a role in glycosaminoglycan binding, the fusion (F) protein, which

55 rophin (PTN) is a multifunctional, cationic, glycosaminoglycan-binding cytokine and growth factor inv

56 Evasin-3 is found to disrupt the glycosaminoglycan-binding site of CXCL8 and inhibit the

57 cluding those involved in Golgi trafficking, glycosaminoglycan biosynthesis, and glycosylphosphatidyl

58 ctional roles, including major dependency on glycosaminoglycan biosynthesis, sterol regulatory elemen

59 (2) GO term "glycosaminoglycan biosynthetic process" was enriched in

60 This glycosaminoglycan blocks the protective effect of Lys-35

61 he vasculature relies on the presentation of glycosaminoglycan-bound chemokines on the luminal side o

62 We further validate that glycosaminoglycans but not sulfate groups are required f

63 nes are not presented to leukocytes bound to glycosaminoglycans, but rather, in solution while seques

64 nce) and a higher production of collagen and glycosaminoglycans (by histology) compared with the mono

65 Furthermore, we demonstrate that these glycosaminoglycans can block entry of and infection by f

66 ted inhibition is mainly associated with the glycosaminoglycan chains of CSPGs, and chondroitin-4-sul

67 Glycosaminoglycan chains of keratan sulfate proteoglycan

68 those proteins, and enzymes that can modify glycosaminoglycan chains of proteoglycans.

69 Through sulfated groups on their glycosaminoglycan chains, heparan sulfate proteoglycans

70 e show that heparan sulfate (HS), a class of glycosaminoglycan chains, regulates the number and asymm

71 h its core protein and with Ptc1 through its glycosaminoglycan chains.

72 moduli, biochemical content (i.e., sulfated glycosaminoglycans, collagen), and histological staining

73 Hyaluronan (HA) is a major glycosaminoglycan component of the ECM and plays a signi

74 Hyaluronan is the predominant glycosaminoglycan component of the extracellular matrix

75 It is a linear glycosaminoglycan composed of disaccharide units of GlcN

76 om differences in intracellular HA, sulfated glycosaminoglycan concentration, apoptosis, or levels of

77 We observed abnormal glycosaminoglycan concentrations and increased concentra

78 ved from affected individuals and determined glycosaminoglycan concentrations in these cells as well

79 4.7 degrees , T2* was highly correlated with glycosaminoglycan content (r = 0.85, P < .001), the coll

80 Mature samples also exhibited greater glycosaminoglycan content and type II collagen fibre ali

81 ed cellularity, less vascularity, and higher glycosaminoglycan content when compared with control sam

82 vivo human hip cartilage correlates with the glycosaminoglycan content, equilibrium modulus, and coef

83 ing of mouse femurs was performed to measure glycosaminoglycan content, thickness, and volume of the

84 Cellularity and glycosaminoglycans content were significantly higher in

85 age, while the ultimate strain and amount of glycosaminoglycans decreased when age increased.

86 Wnt and Hedgehog signal pathways as well as glycosaminoglycan degradation.

87 upported that roseltide rT1 enters cells via glycosaminoglycan-dependent endocytosis, and enters the

88 chondroitinase-ABC concentrations (mimicking glycosaminoglycan depletion) decreased diffusivities and

89 d ADSCs in the hydrogel, by showing enhanced glycosaminoglycan deposition and expression of chondroge

90 t catabolic stimulation for their effects on glycosaminoglycan deposition as assessed by Alcian blue

91 ds on anabolic gene expression and increased glycosaminoglycan deposition.

92 fractions of the exudate (46.7% increase in glycosaminoglycan deposition; approximately 20% upregula

93 be weakened by charge screening or enzymatic glycosaminoglycan digestion.

94 Other than their highly modified glycosaminoglycans (e.g. fucosylated chondroitin sulfate

95 we show that CD44, a major receptor for the glycosaminoglycan ECM component hyaluronan, coordinates

96 ans (eg, versican, syndecans, biglycan), and glycosaminoglycans (eg, hyaluronan, heparan sulfate) are

97 Sulodexide, a glycosaminoglycan, exerts antithrombotic and profibrinol

98 leaflets exhibit two distinct collagen- and glycosaminoglycan-expressing interstitial cell clusters,

99 ARS-CoV-2), aminopeptidase N (for 229E), and glycosaminoglycans (for OC43).

100 llness is associated especially with altered glycosaminoglycan, GABAergic synapse, sialylation, and p

101 A27 is one of the three glycosaminoglycan (GAG) adhesion molecules and binds to

102 Oligomerization and glycosaminoglycan (GAG) binding of CCL5 and CCL3 are vit

103 en identified a suite of enzymes involved in glycosaminoglycan (GAG) biogenesis and transport, includ

104 Among glycosaminoglycan (GAG) biosynthetic enzymes, the human

105 ored in platelet alpha-granules bound to the glycosaminoglycan (GAG) chains of serglycin.

106 was to provide imaging evidence of increased glycosaminoglycan (GAG) content in patients with post-st

107 Glycosaminoglycan (GAG) enrichment is a dominant hallmar

108 Heparin and related members of the glycosaminoglycan (GAG) family are highly polyanionic li

109 newly identified xylose kinase essential for glycosaminoglycan (GAG) formation on the protein core of

110 r without heparan and/or chondroitin sulfate glycosaminoglycan (GAG) modifications in cells and has e

111 that it is also bound to large interstitial glycosaminoglycan (GAG) networks in different tissues, w

112 Glycosaminoglycan (GAG) polysaccharides have been implic

113 Food grade sulfated glycosaminoglycan (GAG) polysaccharides were successfull

114 des as well as non-protein factors including glycosaminoglycan (GAG) polysaccharides.

115 t combining LIPUS with microbubbles enhanced glycosaminoglycan (GAG) production by 17% (5% with LIPUS

116 Glycosaminoglycan (GAG) sequences that selectively targe

117 ce sulfatase Sulf1 against its physiological glycosaminoglycan (GAG) target heparan sulfate (HS) by s

118 Semi-synthetic glycosaminoglycan (GAG), generated from the sulfation of

119 Moreover, 1B6 recognized glycosaminoglycan (GAG)-bound CXCL10, resulting in targe

120 e the promising therapeutic potential of the glycosaminoglycan (GAG)-like molecule pentosan polysulfa

121 Proteoglycans (PGs), a family of glycosaminoglycan (GAG)-protein glycoconjugates, contrib

122 It has been shown extensively that glycosaminoglycan (GAG)-protein interactions can induce,

123 Glycosaminoglycan (GAG)-protein interactions mediate cri

124 Degradation of the endothelial glycocalyx, a glycosaminoglycan (GAG)-rich layer lining the vascular l

125 dimers, and mediates its function by binding glycosaminoglycans (GAG) and CXCR2 receptor.

126 Glycosaminoglycans (GAG) are important regulators of ang

127 mple synthetic glycans, more complex natural glycosaminoglycans (GAG), and lectins/carbohydrate bindi

128 These peptides display high affinity for glycosaminoglycans (GAGs) and compete with functional in

129 E367 enhanced the viral binding affinity for glycosaminoglycans (GAGs) and reduced viremia levels and

130 his could be mediated by the xyloside-primed glycosaminoglycans (GAGs) and that these differ in compo

131 Glycosaminoglycans (GAGs) are a class of heterogeneous,

132 ractions between chemokines such as CCL5 and glycosaminoglycans (GAGs) are essential for creating hap

133 Glycosaminoglycans (GAGs) as one major part of the glyco

134 Glycosaminoglycans (GAGs) bind all known amyloid plaques

135 to heparin and brain-derived heparan sulfate glycosaminoglycans (GAGs) but not to the closely related

136 all-beta conformation, which interacts with glycosaminoglycans (GAGs) but not with the specific XCL1

137 Structural characterization of sulfated glycosaminoglycans (GAGs) by mass spectrometry has long

138 are mediated through the negatively charged glycosaminoglycans (GAGs) chondroitin sulfate and high-m

139 Glycosaminoglycans (GAGs) govern important functional ch

140 Cell surface glycosaminoglycans (GAGs) have been identified as CHIKV

141 es in control of mineralization, the role of glycosaminoglycans (GAGs) is less clear.

142 o susceptible host cells by interacting with glycosaminoglycans (GAGs) on the cell surface.

143 Glycosaminoglycans (GAGs) play vital roles in many biolo

144 Glycosaminoglycans (GAGs) represent a promising class of

145 (CS) proteoglycan (CSPG)-associated sulfated glycosaminoglycans (GAGs) that are selectively up-regula

146 lysine at E2 162 or 247 were more reliant on glycosaminoglycans (GAGs) to enter cells and were select

147 sulfate (DS) are l-iduronic acid containing glycosaminoglycans (GAGs) which are implicated in a numb

148 membrane-docking peptide to heparan sulfate glycosaminoglycans (GAGs) with a PTD.

149 nd and lung, we demonstrate that MCK-2 binds glycosaminoglycans (GAGs) with affinities in the followi

150 Glycosaminoglycans (GAGs), a category of linear, anionic

151 th the presentation of CXCL8 on cell-surface glycosaminoglycans (GAGs), an interaction that is vital

152 Glycosaminoglycans (GAGs), especially heparin and hepara

153 tion is intimately coupled to binding tissue glycosaminoglycans (GAGs), heparan sulfate (HS), chondro

154 Heparan sulfate belongs to the group of glycosaminoglycans (GAGs), highly sulfated linear polysa

155 n was demonstrated to interact with sulfated glycosaminoglycans (GAGs), in a Ca(2+)-independent way,

156 e of tissue-specifically expressed, sulfated glycosaminoglycans (GAGs), like HS, in determining FH bi

157 Sema3A interacts with glycosaminoglycans (GAGs), presumably through its C-term

158 te and present CXCL12 via cell-surface-bound glycosaminoglycans (GAGs), thereby attracting CLL cells

159 Furthermore, HS, heparin, and other related glycosaminoglycans (GAGs), to different extents, can bin

160 most complex and important carbohydrates are glycosaminoglycans (GAGs), which display varied stereoch

161 or damage to elastic fibers, and pooling of glycosaminoglycans (GAGs), with associated losses of med

162 nant envelope protein of vaccinia virus, for glycosaminoglycans (GAGs)-specific targeting and imaging

163 tain non-proteinaceous components, including glycosaminoglycans (GAGs).

164 e inhibitor (serpin) family are activated by glycosaminoglycans (GAGs).

165 heir envelope glycoproteins and cell-surface glycosaminoglycans (GAGs).

166 matory processes, is known to be affected by glycosaminoglycans (GAGs).

167 t are achieved by interactions with sulfated glycosaminoglycans (GAGs).

168 se is intimately coupled to interaction with glycosaminoglycans (GAGs).

169 oteoglycans are proteins that carry sulfated glycosaminoglycans (GAGs).

170 in the IDUA gene causing the accumulation of glycosaminoglycans (GAGs).

171 ted protein 5/6 (Lrp5/6), Tetraspanin-12 and glycosaminoglycans (GAGs).

172 ), antibodies to PF4 and heparin or cellular glycosaminoglycans (GAGs).

173 ns, sialylated oligosaccharides and sulfated glycosaminoglycans (GAGs).

174 ilage matrix comprised of negatively charged glycosaminoglycans (GAGs).

175 Urine GCX breakdown products [glycosaminoglycans (GAGs)] were quantified using dimethy

176 lar matrix, consisting of negatively charged glycosaminoglycans, glycoproteins and proteoglycans in t

177 therapeutically significant glycoconjugates (glycosaminoglycans, glycoproteins, glycolipids, glycosyl

178 lasses of glycan including N- and O-glycans, glycosaminoglycans, glycosphingolipids, and glycophospha

179 We found that the type of glycosaminoglycan has a different effect on the kinetics

180 Hyaluronan, a high molecular mass glycosaminoglycan, has been shown by us to be a suitable

181 These complex glycosaminoglycans have important roles in cell adhesion

182 molecular species, such as glycoproteins and glycosaminoglycans, have important biological and therap

183 Cell surface anionic glycosaminoglycans heparan sulfate and HA protect the ce

184 The glycosaminoglycan heparin inhibits mesangial cell growth

185 The natural glycosaminoglycan heparin surprisingly inhibited malaria

186 tilization hierarchy indicates that the host glycosaminoglycans heparin (Hep) and heparan sulfate (HS

187 n important constituent of the heterogeneous glycosaminoglycans heparin and heparan sulfate occurring

188 sulfate (HS) and chondroitin sulfate B (CSB) glycosaminoglycans; however, the underlying structural m

189 complex sulfation motifs of heparan sulfate glycosaminoglycans (HS GAGs) play critical roles in many

190 king the CD44 transmembrane receptor for the glycosaminoglycan hyaluronan (HA) demonstrate a number o

191 The glycosaminoglycan hyaluronan (HA) is a major extracellul

192 ceptor 4 (TLR4) and the extracellular matrix glycosaminoglycan hyaluronan (HA) on AEC2s are important

193 The high concentration in the stroma of the glycosaminoglycan hyaluronan, together with the large ge

194 dent on RPTPzeta and the other requiring the glycosaminoglycan hyaluronan.

195 The breakdown of the glycosaminoglycan, hyaluronan (HA), by TMEM2 within the

196 accompanied by a coordinate loss in another glycosaminoglycan, hyaluronan.

197 For each class of the glycosaminoglycans-hyaluronan (HA), heparan sulfate/hepa

198 We identify the polyanionic glycosaminoglycans hyaluronic acid and heparan sulfate a

199 c acid-a high molecular extracellular matrix glycosaminoglycan implicated in playing an important rol

200 ace glycan binding proteins which facilitate glycosaminoglycan import into the periplasm; distinct ki

201 n of hyaluronan, a predominant extracellular glycosaminoglycan in developing palatal mesenchyme, play

202 Hyaluronan (HA) is the major glycosaminoglycan in the extracellular matrix.

203 , our study uncovers a novel role of HS-type glycosaminoglycans in a local accumulation of FXIIa on t

204 l-iduronidase activity and clearing elevated glycosaminoglycans in blood and multiple organs.

205 asis is also regulated by negatively charged glycosaminoglycans in the skin interstitium, where sodiu

206 of interest, including lipids, proteins and glycosaminoglycans, in the bioengineered neo-cartilage.

207 CLEC14A physically interacted with other glycosaminoglycans, including endothelial heparan sulfat

208 to probe interactions of AgRP peptides with glycosaminoglycans, including heparan sulfate.

209 blockade of extratumoral chondroitin sulfate glycosaminoglycans inhibits glioblastoma invasion.

210 ion promotes lipoprotein deposition onto BrM glycosaminoglycans, initiating downstream effects that c

211 esults provide a more nuanced picture of PF4-glycosaminoglycan interactions leading to complex format

212 However, the current model of chemokine-glycosaminoglycan interactions, and its implications for

213 sociated with the current model of chemokine-glycosaminoglycan interactions, with implications for th

214 The structural analysis of these glycosaminoglycans is challenging due to the lability of

215 ectrometry analysis was performed to confirm glycosaminoglycan levels and sulfation patterns on donor

216 We also synthesized an orally active glycosaminoglycan (LHbisD4) that specifically binds with

217 glycolic acid (PLGA) microspheres containing glycosaminoglycan-like biopolymers (BPs), was examined.

218 HS is a ubiquitous glycosaminoglycan located on the cell surface and tether

219 d secretion of lysosomal contents, including glycosaminoglycans, lysosomal hydrolases, and matrix met

220 of various periplasmic lyases which dictate glycosaminoglycan metabolic pathways; understanding of e

221 r study fills major gaps in our knowledge of glycosaminoglycan metabolism by the HGM.

222 ection of the genetic loci that orchestrates glycosaminoglycan metabolism in the organism Bacteroides

223 cade, lysosomes, innate immune response, and glycosaminoglycan metabolism.

224 , G protein coupled receptors, serotonin and glycosaminoglycan metabolisms among others.

225 Screening a library of 60 nonsaccharide glycosaminoglycan mimetics (NSGMs) led to the discovery

226 up of small molecules, called non-saccharide glycosaminoglycan mimetics (NSGMs), as direct allosteric

227 gical and immunological significance of this glycosaminoglycan modification and for an "ancient glyca

228 a common, but complex, malignancy-associated glycosaminoglycan modification.

229 S cleaved chemokines at the N terminus with glycosaminoglycans modulating cathepsin processing of ch

230 Both lectins bind specific sugars, including glycosaminoglycan motifs with beta1-3/beta1-4 linkages b

231 flow applicable for simultaneous analysis of glycosaminoglycans, N-glycans and proteins/peptides from

232 Hyaluronan (HA) is a ubiquitous glycosaminoglycan of the extracellular matrix.

233 Hyaluronan (HA), a ubiquitous glycosaminoglycan of the lung extracellular matrix, is r

234 Hyaluronan (HA) is one of the most prevalent glycosaminoglycans of the vascular extracellular matrix

235 ables the long-lived presentation of defined glycosaminoglycans on cell surfaces using HaloTag protei

236 sulfate (HS) and chondroitin sulfate B (CSB) glycosaminoglycans on the cell surface.

237 vivirus nonstructural protein 1 (NS1) alters glycosaminoglycans on the endothelium, causing hyperperm

238 In this study, we investigated the effect of glycosaminoglycans on the kinetics of amyloid fibril for

239 We show that T. vaginalis EVs interact with glycosaminoglycans on the surface of host cells and spec

240 s to placental dysfunction via modulation of glycosaminoglycans on trophoblasts and chorionic villi,

241 ve a variety of accessory molecules, such as glycosaminoglycans, one of the main components of the ex

242 ec-Fc was specifically inhibited by sulfated glycosaminoglycans, particularly heparin and heparan sul

243 tly by the large cross-linked assemblages of glycosaminoglycan present within leukocyte pericellular

244 ECM) is a macromolecular network composed of glycosaminoglycans, proteoglycans, glycoproteins, and fi

245 We posit that glycosaminoglycans provide an immobilized chemokine depo

246 ontent (r = 0.85, P < .001), the collagen-to-glycosaminoglycan ratio (r = -0.79, P < .001), and water

247 hat BTV8H acquired an increased affinity for glycosaminoglycan receptors during passaging in cell cul

248 we show that a genetic point mutation in the glycosaminoglycan recognition motif of Otx2 broadly dela

249 Glycosaminoglycans represent an important, high priority

250 Cartilage sulphated glycosaminoglycan (sGAG) and collagen content were asses

251 A lacking the CROPs, and identified sulfated glycosaminoglycans (sGAGs) and low-density lipoprotein r

252 employ a haploid screen to identify sulfated glycosaminoglycans (sGAGs) as its second glycan receptor

253 Digesting glycosaminoglycan side chains of CSPG with chondroitinas

254 se that specifically degrades the unbranched glycosaminoglycan side chains of HSPGs.

255 rting from the observation that the sulfated glycosaminoglycan-specific peptide exerts a different ef

256 creased in visceral organs of MPS-I animals, glycosaminoglycans storage was reduced, and skeletal phe

257 Urine glycosaminoglycan studies revealed a pathological excess

258 Pathways for the metabolism of various glycosaminoglycan substrates remain ill-defined.

259 ulfate groups of sulfated GalNAc residues of glycosaminoglycans such as chondroitin and dermatan sulf

260 Glycosaminoglycans such as chondroitin sulfate (CS) and

261 ry TGFbeta1 and osteogenic BMP-2, as well as glycosaminoglycans such as heparan sulfate and chondroit

262 lecular mechanisms governing interactions of glycosaminoglycans (such as heparin) with proteins remai

263 The aggregates were found to associate with glycosaminoglycans, suggesting an electrostatic mechanis

264 a carbohydrate sulfotransferase integral to glycosaminoglycan sulfation.

265 ow that biallelic mutations in EXTL3 disturb glycosaminoglycan synthesis and thus lead to a recogniza

266 gar donors were then tested as substrates in glycosaminoglycan synthesis catalyzed by various synthas

267 aran sulfate and following the inhibition of glycosaminoglycan synthesis or sulfation in HCT-8 cells.

268 ter heparan sulfate removal or inhibition of glycosaminoglycan synthesis or sulfation.

269 Blocking sulfation and glycosaminoglycan synthesis reduces TcdA binding and ent

270 NOX4) and pathways (such as proteoglycan and glycosaminoglycan synthesis) involved in growth.

271 y decreased in CHO cell mutants defective in glycosaminoglycan synthesis.

272 A/K45A retained higher affinity for sulfated glycosaminoglycans than K42A/K110A and exhibited increas

273 ndered by the presence of hyaluronan (HA), a glycosaminoglycan that is a major fluid barrier in the i

274 ndation of extracellular matrix proteins and glycosaminoglycans that alter tumor biophysics and signa

275 abolism has been linked to the metabolism of glycosaminoglycans that are exposed on injured heart val

276 g specificity for substructures within these glycosaminoglycans that display a different degree of su

277 contains variable but often large amounts of glycosaminoglycans that influence cell and tissue functi

278 the presence of negatively charged aggrecan glycosaminoglycans that provide swelling pressures, comp

279 tructure, also enhancing the binding of this glycosaminoglycan to its cell surface receptor, CD44.

280 d thus extend the ancestry of this important glycosaminoglycan to the premetazoan era.

281 in human cells and found that RVFV utilizes glycosaminoglycans to attach to host cells.

282 red grafts, based on the quantified ratio of glycosaminoglycans to DNA and histological score, could

283 rate that FXIIa utilizes cell membrane-bound glycosaminoglycans to interact with the cell surface of

284 f murine interferon gamma (IFN-gamma), binds glycosaminoglycans to modulate serum and interstitial cy

285 ad ECs (RFPECs), including proteoglycans and glycosaminoglycans, to observe how each component indivi

286 capacity and changes in urinary excretion of glycosaminoglycans (uGAG).

287 s assayed for glycocalyx breakdown products (glycosaminoglycans) using a dimethylmethylene blue (GAG-

288 des that can be used to differentiate parent glycosaminoglycans via unsupervised multivariate analysi

289 e tool that specifically recognizes sulfated glycosaminoglycans, we analyzed the role of membrane hep

290 he biosynthesis of sialic acids and sulfated glycosaminoglycans were analyzed in the anammox draft ge

291 ins indicated that sialic acids and sulfated glycosaminoglycans were present in the anammox EPS (1.6%

292 d heparan sulfate (Hp/HS) are linear complex glycosaminoglycans which are involved in diverse biologi

293 e and heparan sulfate (HS), as well as other glycosaminoglycans, which are bioactive entities with ph

294 of filamentous proteins, proteoglycans, and glycosaminoglycans, which extensively interact and whose

295 aused a significant loss of TMJ collagen and glycosaminoglycans, which was accompanied by amplificati

296 one side of the protein for interaction with glycosaminoglycans, while the opposite face can bind fib

297 of enzymes that target substructures of the glycosaminoglycans with variable sulfation or that the g

298 Hyaluronan (HA) is an abundant glycosaminoglycan within the extracellular matrix of the

299 Highly sulfated glycosaminoglycans within the cartilage matrix provide s

300 skin interstitium, where sodium is bound to glycosaminoglycans without commensurate effects on extra